baber/WOPTO huggingface dataset:
Patent NZ-503695-A (NZ)
Title: Absorbent article with enhanced elastic design for improved aesthetics and containment
Inventor: ST LOUIS RAYMOND GERARD
IPC: A61F13/00
Filed: 1998-10-16
Abstract: An absorbent article (10) which includes a backsheet layer (30) having a pair of laterally opposed and longitudinally extending side margins (20). Each side margin has an outwardly concave, terminal side edge contour (15) located at appointed leg opening regions (17) in an intermediate portion (16) of the side margin. Each concave side edge contour (15) has a selected longitudinal extent along a length dimension (26) of the article (10). A liquid permeable topsheet layer (28) is connected in a superposed facing relation to the backsheet layer (30), and an absorbent body (32) is sandwiched between the topsheet layer (28) and the backsheet layer (30). A separately provided gusset-flap composite member (19) is connected to at least one of the backsheet and topsheet layers along each of the leg opening regions (17). The gusset-flap member (19) provides a leg gusset section (142) and a containment flap section (144). The gusset-flap member includes a barrier layer (174) having a pair of laterally opposed, longitudinally extending, barrier layer side edges (140, 141), and has a first major facing surface (148) and a second major facing surface (149). A nonwoven fabric layer (176) is joined in facing relation with the first facing surface (148) of the barrier layer (174). The fabric layer (176) has a leg gusset region (136), an outboard side portion (170), a containment flap region (63), and an inboard side portion (62). The outboard side portion (170) of the gusset-flap fabric layer (176) is arranged to wrap around at least one side edge of the barrier layer (174) and to extend inboard therefrom along the second facing surface (149) of the barrier layer (174). A first arrangement of a first plurality of separate, longitudinally extending elastomeric members (138) are attached and interposed between the barrier layer (174) and the fabric layer (176) within the leg gusset section (142) of the gusset-flap member (19).
Patent NZ-504364-A (NZ)
Title: Method of plasma incision of matter with a specifically tuned radiofrequency electromagnetic field generator
Inventor: FUGO RICHARD J
IPC: H05H1/24
Filed: 1998-09-24
Abstract: A method of incising matter with a harmonious plasma cloud. An inexpensive radiofrequency generator and power amplifier generates an electromagnetic wave which is transmitted from an incising transmitter probe. This electromagnetic wave is impedance matched, frequency matched, and power matched to initiate and sustain a harmonious plasma cloud with low atomic particle turbulence and chaos. This harmonious plasma cloud forms a coating over the surface of the incising tip as well as acts to reduce the energy output needed from the power amplifier. The electromagnetic wave is also used to produce a Pinch Effect to compress, contour, shape and control the harmonious plasma cloud. The electromagnetic wave is furthermore used to trap and contain the plasma cloud without the need of a solid matter containment vessel according to the Magnetic Bottle Effect of physics. The Tunnelling effect of physical chemistry is utilized to amplify the energy delivered to the harmonious plasma cloud while shielding matter surrounding the intended path of incision from potential radiation exposure. The system provides an efficient, effective, safe, clean and inexpensive approach to producing an incision in matter.
Patent NZ-506091-A (NZ)
Title: Circulating insulin-like growth factor-i and prostate cancer risk
Inventor: POLLACK MICHAEL N
IPC: G01N33/574
Filed: 1999-01-21
Abstract: A method of predicting increased risk of prostate cancer in an individual without prostate cancer. It involves the measuring the concentration of insulin-like growth factor (IGF-I) in a body fluid from an individual. An elevated concentration of IGF above a reference range for IGF indicates an increased risk for prostate cancer in the future. Body fluid used may include blood, plasma, serum and seminal fluid. Additionally, the concentrations of IGF-I and insulin-like growth factor-1 (IGFB-3) are measured. A multivariate adjustment of IGF-I concentration relative to IGFB-3 provides an adjusted IGF-I level. Where such a level is above a reference range for adjusted IGF-I indicates an increased risk for prostate cancer in the future. A multivariate adjustment of the IGF-I concentration relative to the PSA concentration to provides an adjusted IGF/PSA value. Where such a value is above the reference range for adjusted IGF/PSA indicates an increased risk for prostate cancer in the future with a poor prognosis. A multivariate adjustment of the IGF-I concentration relative to IGFBP and PSA concentrations to provide an adjusted IGF/PSA value. Where such a value is above the reference range for adjusted IGF/PSA indicates an increased risk for severe prostate cancer in the future. IGF-I concentrations are compared to a reference group without prostate cancer to establish a reference level.
Patent NZ-507782-A (NZ)
Title: G-CSF receptor agonist antibodies and screening method therefor
Inventor: NI BAOFU
IPC: A61K35/76
Filed: 1999-04-30
Abstract: An agonist antibody that specifically binds to human G- CSF receptor to stimulate cell proliferation and differentiation, wherein each CDR of the heavy chain variable region of the antibody includes a sequence selected from the following: NYGMN; WINTYTGEPTYAGDFKG; or EGFYGGHPGFDY; and each CDR of the light chain variable region of the antibody includes a sequence selected from the following: KSSQSLLSSRTRKNYLA; WASTRES; or KQSYNLRT. Also covered is a DNA sequence encoding said antibody, and a gene delivery system incorporating said DNA and a use of said antibody in the preparation of a medicament for treating neutropenia.
Patent NZ-507866-A (NZ)
Title: Method and apparatus for detecting defective containers on a conveyor
Inventor: MCINTYRE NORMAN J
IPC: B07C5/34
Filed: 1999-04-30
Abstract: An apparatus for detecting defects in a seam formed between a container having an open top and a metal lid crimped to the open top end comprises a conveyer, at least one detecting device an electrical power source a signal device and an ejector device. The conveyer is for conveying the containers and has a receiving end for receiving the containers and a discharge end for discharging the containers. The detecting device comprises a yoke having a horizontal portion and a pair of spaced-apart, vertical legs extending perpendicular to the conveyer and having first and second electrical contacts mounted in said vertical legs and disposed on opposite sides of said conveyor and being positioned to simultaneously contact said seam when a defect exists in the seam as the container is conveyed past the detecting device without the electrical contacts contacting a properly seamed container. The electrical power source is connected to the first and second electrical contacts. The signal device is connected to the electrical contacts to signal the presence of and to identify containers having a defective seam. The ejector device is positioned downstream of the detecting device and ejects the containers having a defective seam. The signal device is connected to the ejector device to actuate the ejector device at a predetermined time sequence to eject a container having a detected seam from the conveyor. Also described is a method for separating a container having a defective seam from a plurality of containers. The method comprises the steps of positioning the containers on the receiving end of the conveyor and conveying the containers through the apparatus. The apparatus produces a signal in response to a container having a defective seam contacting the electrical contacts and then ejects the container with the defective seam from the conveyer.
Patent NZ-511150-A (NZ)
Title: Non-fermented osmotic laxative for treating and preventing colorectal cancers
Inventor: CORPET DENISE E
IPC: A61K31/765
Filed: 1999-05-05
Abstract: Use  of a non-fermented osmotic laxative as an  active agent  for  preparation of a medicinal product for  treating and/or  preventing colon and/or rectum cancers. A method  of treating  or  preventing colon or rectum  cancer  comprising administering  to  a  mammal  a  therapeutically   effective amount of a non-fermented osmotic laxative
Patent NZ-514624-A (NZ)
Title: Gable or fascia bracket attached to gable or fascia board and then bent around, overlapped and fastened to end timber
Inventor: MCKENZIE WILLIAM LAWRENCE
IPC: E04D13/15
Filed: 2001-10-03
Abstract: Bracket 1 is fastened to fascia board 20. It allows for fastening to gable end timber 21 by bending around, overlapping and fastening to timber 21.
Patent NZ-523290-A (NZ)
Title: Improvements in cable-less (wireless) electronic weighing systems using infrared link or radio frequency signals
Inventor: LUNENBURG PIETER CORNELIS
IPC: G01G23/00
Filed: 2002-12-20
Abstract: A weighing apparatus including loadbars (11) and a weight indicator (10) that communicates with the loadbars via radio signals using frequency division multiplexing or time division multiplexing. Each loadbar may have its own environmentally sealed power source (16) supplying power via inductive transfer, or the apparatus may include a single power source connected to at least one of the loadbars by inductive power transfer, with power supplied to other loadbars via hard wire connections. The power source or sources utilise wireless communication with the indicator to transmit weighing data and to receive signals enabling power switching to reduce power usage. The power source or sources exchange data with loadbars by means of radio or infra-red communication, or by modulation of the power transfer flux.
Patent NZ-524032-A (NZ)
Title: 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine2,4-dione, D(-)tartrate salt or a solvate thereof
Inventor: CHOUDARY BERNADETTE MARIE
IPC: A61P3/10
Filed: 2001-08-03
Abstract: A pharmaceutical compound 5-[4-2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, D(-) tartrate salt or a solvate thereof, a process for preparing such a compound, a pharmaceutical composition comprising such a compound and the use of such a compound in medicine for the treatment and/or prophylaxis of diabetes mellitus and conditions associated with diabetes mellitus is disclosed.
Patent NZ-524034-A (NZ)
Title: Methods for modulating multiple lineage kinase proteins and screening compounds which modulate multiple linease kinase proteins
Inventor: MARONEY ANNA
IPC: A61P17/02
Filed: 2001-08-08
Abstract: Disclosed herein is a use of a compound of formula (I) that inhibits a multiple lineage kinase (MLK) protein for the manufacture of a medicament for treating AIDS peripheral neuropathy, wherein the variables shown in formula (I) are as defined in the specification.
Patent NZ-526283-A (NZ)
Title: Vaccine composition containing human transforming growth factor alpha fused to a carrier protein and optionally contain an EGF-R ligand
Inventor: MULET SIERRA AILLETTE
IPC: A61K47/48
Filed: 2001-12-06
Abstract: Disclosed is a vaccine preparation able to provoke an immune-castration of self-TGFalpha useful for the active immunotherapy of malignant tumors that depend of TGFalpha for its growth, as well as for the treatment of other TGFalpha dependent diseases. Also disclosed is a vaccine composition containing a combination of TGFalpha with other EGF-R ligands, such as epidermal growth factor (EGF), able to inhibit the proliferation of tumors whose progression depends on these factors. Resistance generated by tumors vaccines containing each molecule for separate, developing tumorigenic phenotype that do not depend on the growth factor used in the vaccination can be avoided. These vaccine preparations are able to inhibit the proliferation of tumors with the characteristics mentioned before, and in this way to be useful in the treatment of malignant neoplasias.
Patent NZ-527492-A (NZ)
Title: Gas lift valve with central body venturi for controlling the flow of injection gas in oil wells producing by continuous gas lift
Inventor: DE ALMEIDA ALCINO RESENDE
IPC: E21B34/06
Filed: 2002-01-17
Abstract: The present invention relates to a gas lift valve for use in an oil well producing by means of gas lift, said gas lift valve making use of a central body venturi for both controlling the flow of the injection gas from the annulus between the tubing and the casing of the oil well, and precluding a reverse flow of fluids from said oil well towards said annulus to occur.
Patent NZ-530237-A (NZ)
Title: Subtilase variants
Inventor: FANO TINA SEJERSGARD
IPC: C12N1/19
Filed: 2002-07-11
Abstract: A variant of a substilase belonging to the sub-group I-S2 comprises at least the alteration V68A in combination with an alteration in one or more positions selected from 48; 51; 106; 131; 139; 158; 168 and 203. The variant substilase can be used in a cleaning or detergent composition.
Patent NZ-530526-A (NZ)
Title: A method and system for analyzing motion transferred to a subject on a sleeping surface
Inventor: GLADNEY RICHARD F
IPC: G01M99/00
Filed: 2002-07-03
Abstract: A method and system for analysing the transfer of motion to a subject body on a sleeping surface. A mattress is positioned on a stationary frame, and a subject is positioned on the mattress. Sensors are placed in communication with the subject. The surface adjacent the subject is moved by means of a moving mass, and the sensors detect the motion of the subject. Motion transferred to the subject as a result of the mattress moving is measured and recorded.
Patent NZ-532331-A (NZ)
Title: Purification of tyrosine kinase receptor-related polypeptides that does not require a refolding step and has a higher yield and is commercially viable
Inventor: DAWBARN DAVID
IPC: C07K19/00
Filed: 2002-09-17
Abstract: A purification method is described, particularly for purifying tyrosine kinase receptor related polypeptides, and products made by the method. The method comprises a method of producing tyrosine kinase receptor-related polypeptides, the method comprising expressing a tyrosine kinase receptor-related polypeptide in a recombinant expression system and separating expressed monomeric tyrosine kinase receptor-related polypeptide from multimeric form(s) of the expressed polypeptide in a separation step; the separation step allowing refolding of the expressed tyrosine kinase receptor-related polypeptide into a biologically active form. The figure depicts an overlap of traces from an FPLC machine illustrating comparative experiments with a prior art dialysis method and a method described herein;
Patent NZ-532562-A (NZ)
Title: Use of an FPT inhibitor in combination with other antineoplastic agents for the manufacture of a medicament to be used in the treatment of cancer
Inventor: CUTLER DAVID L
IPC: A61K33/243
Filed: 2002-11-25
Abstract: Disclosed is the use of a farnesyl protein transferase inhibitor of formula (1.1), Cisplatin and Gemcitabine in the manufacture of a medicament for simultaneous, sequential or separate use for the treatment of cancer.
Patent NZ-534867-A (NZ)
Title: Method and apparatus for the continuous fractionation of biological fluids
Inventor: BRIGGS DENNIS A
IPC: A61M1/36
Filed: 2003-02-28
Abstract: Systems, methods and apparatus for improving the yield for separating components of fluids, for example biological or sensitive fluids such as blood, and improving the component yield, for example, from donated whole blood by separating its components by density in a centrifuge bowl with a multi-axial lumen. The apparatus, system, and method eliminate the need to batch-type separate blood and can reduce the time needed to treat patients suffering from T-cell or white blood cell mediated diseases or conditions to less than 70 minutes. Described is a centrifuge bowl (10) comprising an outer housing (100); a core (200); a lower plate (300); a lumen (400); a first bowl channel (420) within the lumen for inflowing the fluid (800); a second bowl channel (410) for removing a first separated fluid component (810); and a third bowl channel (740) for removing a second separated fluid component (820).
Patent NZ-535747-A (NZ)
Title: Motion tracking system and method
Inventor: MENACHE ALBERTO
IPC: H04W64/00
Filed: 2003-03-11
Abstract: A method for tracking object movement, comprises the steps of: placing a plurality of sensors (14) around a capture zone (20); placing a stationary reference tag within the capture zone; coupling at least one tag (12) on at least one object (18) to be tracked in the capture zone (20); periodically transmitting signals from the reference tag and at least one object tag (12); receiving the signals at the sensors (14); determining code phase and carrier phase measurements for each signal received; and processing the code phase and carrier phase measurements to determine the position of the at least one tag with respect to the reference tag.
Patent NZ-538336-A (NZ)
Title: Implant for implanting in bone tissue or in bone tissue supplemented with bone substitute material
Inventor: MAYER JORG
IPC: A61F2/00
Filed: 2003-08-15
Abstract: An implant for implanting in bone tissue, for example, a dental implant or an implant for an orthopedic application. This implant has surface areas (4) of first type that have, for example, osseointegrative, anti-inflammatory, infection-fighting and/or growth-promoting properties, and has surface areas (8) of a second type that are comprised of a material that can be liquefied by mechanical vibrations. The implant is positioned inside an opening, e.g. of a jaw-bone, is subjected to the action of mechanical vibrations, e.g. ultrasound, and is pressed against the jaw-bone. During this process, the liquefiable material is liquefied and pressed into uneven areas and pores of the surrounding bone tissue where, upon resolidification, it forms a positive connection between the implant and the bone tissue. An appropriate arrangement and dimensioning of the surface areas of the first and second types results in, during implantation, the liquefied material flowing, at most, in a clinically irrelevant amount over the surface areas of the first type so that the biologically integrative properties of these surface areas can become effective immediately after implantation. Due to the positive connection, the implant acquires a very good primary stability whereby enabling it to be placed under stress immediately after implantation. This prevents the occurrence of a negative effect as a result of not placing the implant under stress and reduces relative movements between the implant and bone tissue to a physiological extent that is conducive to a desired osseointegration after implantation.
Patent NZ-538367-A (NZ)
Title: 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition
Inventor: ROTH GERALD J
IPC: A61K31/496
Filed: 2003-07-18
Abstract: Disclosed is the compound 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene-6-methoxycarbonyl-2-indolinone-monoethanesulphonate of formula (I) and the use thereof in the preparation of a pharmaceutical composition which is suitable for treating excessive or abnormal cell proliferation.
Patent NZ-538695-A (NZ)
Title: Retained Satellite Ring Cap and Bottle Assembly
Inventor: NOONAN MICHAEL PATRICK
Filed: 2003-09-09
Abstract: A retained satellite ring cap having an outer skirt adapted for engagement with a bottle neck and a satellite tamper evident ring connected by at least one frangible connector to the outer skirt. Satellite tamper evident ring having retaining means adapted for engagement with the bottle neck. Satellite ring including a transitional wall which extends upwardly and inwardly from the satellite ring to immediately below a lower edge of the outer skirt and is linked by at least one frangible connector to the outer skirt. The arrangement being such that when the cap is fitted to a bottle, the tamper evident ring is located with the retaining means engaged with the bottle neck. On twisting removal of the cap, at least one frangible connector is broken, allowing the cap to be removed while the satellite tamper evident ring is retained in position on the bottle neck by the retaining means. (62) Divided Out of 521268
Patent NZ-541732-A (NZ)
Title: Unique fabric structure for industrial fabrics
Inventor: DAVENPORT FRANCIS L
IPC: D21F1/00
Filed: 2004-01-30
Abstract: An industrial process fabric and a method for manufacturing such a fabric. The fabric is made of material and is endless, or made endless with a seam, in the machine direction of a machine on which it is used. The fabric comprises at least one layer composed of a spirally-wound strip made of material and having a width which is smaller than the width of the final fabric. The longitudinal axis of the spirally-wound strip of material makes an angle with the machine direction of the fabric. The fabric strip of material may advantageously be a flat-woven fabric of MD and CD yarns in any weave pattern.
Patent NZ-548325-A (NZ)
Title: Mutants of anti-CD40 antibody
Inventor: TAKAHASHI NOBUAKI
IPC: C07K16/28
Filed: 2004-12-24
Abstract: Disclosed is a monoclonal antibody consisting of, (i) two heavy chains, each comprising a constant region derived from a human IgG4 with substitution of serine with proline at position 228 and substitution of leucine with glutamic acid at position 235 and a variable region from a heavy chain of a monoclonal antibody produced by the hybridoma 4D11 (Accession No. FERM BP-7758), and (ii) two light chains, each comprising a variable region from a light chain of a monoclonal antibody produced by the hybridoma 4D11 (Accession No. FERM BP-7758).
Patent NZ-551371-A (NZ)
Title: Polymorphic forms of methyl (+)-(S)-alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-C]pyridine-5(4H) acetate hydrobromide, clopidrogel hydrobromide
Inventor: LORIMER KEITH RICHARD
IPC: C07D495/04
Filed: 2005-04-18
Abstract: Disclosed is an amorphous polymorph of methyl (+)-(S)-alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-C]pyridine-5(4H) acetate hydrobromide, also known as clopidrogel hydrobromidem with an FTIR spectrum with peaks as described in the specification. Also disclosed is the use of the polymorph for inhibiting platelet aggregation or reducing atherosclerotic events.
Patent NZ-551828-A (NZ)
Title: A method of cell isolating a homogenous population of mammary stem cells using specific cell surface marker proteins
Inventor: LINDEMAN GEOFFREY JOHN
IPC: A61K35/55
Filed: 2005-05-12
Abstract: Disclosed is a method for isolating a substantially homogenous population of mammary stem cells (MASCs). The MaSCs are isolated on the basis of differential levels of cell surface marker proteins, and the cells are characterized by being CD45lo, Lin(TER119)lo, CD31lo, CD24hi and CD29hi. The MaSCs of the present disclosure are particularly useful as targets for identifying agents which modulate MaSC survival, self-renewal, proliferation and/or differentiation in both normal and diseased tissue such as, but not limited to, tumor tissue, and, also as source of tissue for the regeneration, replacement and/or augmentation of tissue damaged and/or lost after disease or injury.
Patent NZ-551970-A (NZ)
Title: New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt
Inventor: BOHLIN MARTIN
IPC: A61K31/4439
Filed: 2005-06-20
Abstract: Disclosed is a process for preparing an esomeprazole sodium salt, comprising: i) Dissolving esomeprazole neutral form in toluene, ii) Adding an addition solvent selected from methanol, ethanol, and isopropyl alcohol, iii) Adding about 1 molar equivalents of a sodium salt of a suitable base B, iv) Allowing the esomeprazole sodium salt to crystallize and isolating the formed salt. Also disclosed is an esomeprazole sodium salt obtained by the process. Also disclosed are three esomeprazole sodium salt, each with X-ray diffraction patterns as described herein.